MiMedx Group (NASDAQ: MDXG), which had previously been given a “buy” recommendation by StockNews.com’s equities research analysts, was given a “strong-buy” rating in a note to investors published on Wednesday.

In a separate analysis published on Thursday, March 2, HC Wainwright reaffirmed a “buy” rating on shares of MiMedx Group and set a target price of $8.00 for the company’s stock.
The NASDAQ: MDXG stock started trading at $3.57 on Wednesday.

The business has a $407.27 million market capitalization, a price-to-earnings ratio of -10.82, and a beta of 1.60.

The company has a simple moving average of $4.04 for the last 50 days and a simple moving average of $3.39 for the last 200 days.

The 52-week low for MiMedx Group is $2.43, while the 52-week high for the company is $5.05.

MiMedx Group (NASDAQ: MDXG) disclosed the results of its most recent quarterly financial report on February 28.

The firm reported earnings per share for the quarter to be $0.02, consistent with the $0.02 forecast provided by industry analysts.

The quarter’s sales were $74.38 million, compared to analyst projections of $74.31 million.

According to the findings of stock research experts, MiMedx Group will have a loss of -0.06 cents per share this year.

Peter M. Carlson, the Chief Financial Officer of MiMedx Group, sold 19,000 shares of the company’s stock on Thursday, February 23, according to some other recent developments.

These shares were sold for an average price of $4.50 each, which resulted in a total revenue of $85,500.00.

As a result of the sale, the chief financial officer now has 546,206 shares of the company, which are worth a combined total of $2,457,927.

A filing with the Securities and Exchange Commission made the transaction public knowledge; this file can be located on the website of the SEC.

Peter M. Carlson, the Chief Financial Officer of MiMedx Group, sold 19,000 shares of the company’s stock on Thursday, February 23, according to some other recent developments.

These shares were sold for an average price of $4.50 each, resulting in a total revenue of $85,500.00.

As a result of the sale, the chief financial officer now has 546,206 shares of the company, which are worth a combined total of $2,457,927.

A filing with the Securities and Exchange Commission made the transaction public knowledge; this file can be located on the website of the SEC.

In addition, Chief Administrative Officer William Frank Iv Hulse sold 15,555 shares of the company’s stock on Thursday, February 23.

The price per share averaged out to be $4.53, and the total amount received for the shares was $70,464.15.

Because of the transaction, the chief accounting officer now has direct ownership of 349,361 shares of company stock, which have a combined value of $1,582,605.33.

The disclosure for this sale can be found at this location.

Insiders have sold 67,354 shares of company stock with a total value of $287,943 over the past ninety days. Company insiders hold a 19.60% ownership stake.

Recent corporation transactions include sales of shares by hedge funds and other institutional investors.

Throughout the first three months of the year, Federated Hermes INC significantly raised its holdings in MiMedx Group by 2,943.6%.

After purchasing an additional 1,662,278 shares during the period, Federated Hermes INC now has 1,718,749 shares of the company’s stock, worth $8,095,000.

These shares were acquired during the period.

A 28.9% rise in Vanguard Group INC’s ownership of MiMedx Group was completed during the company’s third fiscal quarter. Vanguard Group INC now has 6,018,658 shares of the company’s stock, valued at $17,274,000, following the acquisition of an additional 1,349,728 shares during the period in question. Nantahala Capital Management LLC initiated a new investment in MiMedx Group during the fourth quarter worth $3,190,000.

The percentage of ownership in MiMedx Group held by Paradigm Capital Management INC grew by 2,544.9% during the third quarter. Following further purchases of 1,094,300 shares during the time frame in question, Paradigm Capital Management INC now holds 1,137,300 shares of the company’s stock, valued at $3,264,000. Finally, during the third quarter, Royce & Associates LP initiated a new stake in MiMedx Group worth $1,564,000.

Institutional investors own the stock to the extent of 56.56 percent.

In addition to providing services for tissue processing, MiMedx Group, INC is a therapeutic biologics firm responsible for developing, manufacturing, and marketing its products. Wound care, burn care, surgery, orthopedics, spine care, sports medicine, ophthalmology, and dentistry are some services offered here.

Among its biomaterial platform technologies are AmnioFix and EpiFix, which are tissue allografts derived from the amnion and chorion layers of the human placental membrane; EpiCord and AmnioCord, which are tissue allografts derived from umbilical cord tissue; and AmnioFill, which is a placental connective tissue matrix derived from the placental disc and other placental tissue.

The post StockNews.com has upgraded MiMedx Group (NASDAQ:MDXG) to “Strong-Buy.” appeared first on Best Stocks.